Implications for the 8P12-11 Genomic Locus in Breast Cancer Diagnostics and Therapy: Eukaryotic Initiation Factor 4E-Binding Protein, EIF4EBP1, As an Oncogene
Total Page:16
File Type:pdf, Size:1020Kb
Medical University of South Carolina MEDICA MUSC Theses and Dissertations 2018 Implications for the 8p12-11 Genomic Locus in Breast Cancer Diagnostics and Therapy: Eukaryotic Initiation Factor 4E-Binding Protein, EIF4EBP1, as an Oncogene Alexandria Colett Rutkovsky Medical University of South Carolina Follow this and additional works at: https://medica-musc.researchcommons.org/theses Recommended Citation Rutkovsky, Alexandria Colett, "Implications for the 8p12-11 Genomic Locus in Breast Cancer Diagnostics and Therapy: Eukaryotic Initiation Factor 4E-Binding Protein, EIF4EBP1, as an Oncogene" (2018). MUSC Theses and Dissertations. 295. https://medica-musc.researchcommons.org/theses/295 This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact [email protected]. Implications for the 8p12-11 Genomic Locus in Breast Cancer Diagnostics and Therapy: Eukaryotic Initiation Factor 4E-Binding Protein, EIF4EBP1, as an Oncogene by Alexandria Colett Rutkovsky A dissertation submitted to the faculty of the Medical University of South Carolina in fulfillment of the requirements for the degree of Doctor of Philosophy in the College of Graduate Studies Biomedical Sciences Department of Pathology and Laboratory Medicine 2018 Approved by: Chairman, Advisory Committee Stephen P. Ethier Co-Chairman Robin C. Muise-Helmericks Amanda C. LaRue Victoria J. Findlay Elizabeth S. Yeh Copyright by Alexandria Colett Rutkovsky 2018 All Rights Reserved This work is dedicated to the fight against cancer. ACKNOWLEDGEMENTS I would like to acknowledge the Hollings Cancer Center and many departments at the Medical University of South Carolina for investing the resources and training required to complete the research presented. This research was also supported in part by the Department of Pathology and Laboratory Medicine at the Medical University of South Carolina and grants from the National Institute of Health awarded to Dr. Stephen Ethier. I would like to thank the Ethier laboratory, both past and present, which have been instrumental in the presented work. I stand on the shoulder of giants, thankful for the many brilliant and dedicated scientists before me and alongside me, especially collaborative, combined, and applied knowledge which allows the mining of big data presented. I am truly grateful for the many faculty and staff at the Medical University of South Carolina and Appalachian State University who have dedicated much effort towards my scientific training, passions, and procurement of resources detrimental to the work presented. Special thanks to my committee members for their wealth of knowledge, advice, help, and ideas, especially Dr. Stephen Ethier and Dr. Stephen Guest who were instrumental in teaching me the skills necessary to complete this work. Materials relied on the unwavering support of Dr. Robin C. Muise-Helmericks and Dr. Elizabeth Yeh. This research would not have been possible without the support from my family, friends, and the community. iv TABLE OF CONTENTS List of Tables viii List of Figures ix-xii Abstract xiii Chapter I: Background 1 Human mammary tissue and breast cancer 2-12 Gene amplification in cancer 13-15 Driving oncogenes on amplicons 16-19 Amplification of the 8p12-11 genomic locus 20-22 Eukaryotic Initiation Factor 4E-Binding Protein (4EBP1, EIF4EBP1) 23-34 4EBP1 and mTOR in mRNA translation 34-36 Genomic location of 4EBP1 36 Conservation among species demonstrates 4EBP1 necessity 37-38 The behavior and expression of 4EBP1 in normal cells 39-40 4EBP1 is highly overexpressed in many malignant tumor types 41-42 4EBP1 transcripts are rarely mutated 43-44 What causes the increase in 4EBP1 transcript levels? 45 Viruses 45-46 Transcription Factors 47-49 Gene amplification 50-52 4EBP1 in cell signaling in breast cancer 53-57 Chapter II: Materials and Methods 58-74 Chapter III: Results 75 v Evidence suggests 4EBP1 is important to many cancer types 76-77 EIF4EBP1 expression levels correlate with reduced relapse free survival 78-79 in human breast cancer 4EBP1 is not required for normal mammary cell proliferation 80-81 4EBP1 is highly expressed and phosphorylated in 8p11-12 breast cancer 82-84 cells Phosphorylated AKT levels and phosphorylated S6 levels across the 85-88 models 4EBP1 knockdown is detrimental to ER+ 8p11-12 breast cancer cells 89-90 Downregulation of 4EBP1 in ER+ 8p11-12 breast cancer cells causes 91-92 cell cycle arrest 4EBP1 knockdown inhibits proliferation of ER- 8p11-12 amplified breast 93-94 cancer cells The effects of 4EBP1 knockdown on non-amplicon bearing cancer cell 95-97 models Loss of 4EBP1 does not promote changes in apoptosis associated 98-99 proteins The decrease in ERα with 4EBP1 loss does not alter protein levels of 100-102 NSD3 or ASH2L 4EBP1 knockdown decreases MYC levels 103-105 Chapter IV: Discussion 106-116 Chapter V: Future Directions 117 Future directions related to 4EBP1 in cell dynamics 118-121 vi A role for 4EBP1 in transformation 121-122 A role for 4EBP1 in growth factor independence 122-123 A role for 4EBP1 in anchorage-independent growth 123 A role for 4EBP1 to bypass senescence 124-125 A role for 4EBP1 to influence cancer stemness 125-126 A role for 4EBP1 in apoptosis 126 A role for 4EBP1 in adipogenesis and lipid metabolism 127-128 A role for wild-type 4EBP1 transcripts in malignant neoplasms 129 A role for 4EBP1 as an antiviral strategy 129-130 A role for 4EBP1 in translation 130-131 A role for 4EBP1 in precision medicine 131-135 Chapter VI: Appendix 136 The 8p11-12 amplicon candidate oncogenes in breast cancer 137 Data mining results of 8p11-12 oncogenes in cancer 138-181 Summarized gene ontologies for 8p11-12 gene involvement in cancer 182-183 transformation processes Available lentiviral 8p11-12 gene expression plasmids for future studies 183-184 Discussion of 8p11-12 data mined results 185-186 References 187-214 Biographical Sketch 215 vii LIST OF TABLES Table 1. Highlights of genomic, clinical and proteomic features of molecular 7 breast cancer subtypes from The Cancer Genome Atlas Network (2012) Table 2. Breast cell line requirements and growth conditions 60 Table 3. Required additions to medium for growth of cell lines in culture 61 Table 4. Short-hairpin RNA plasmids from The RNAi Consortium’s (TRC) 63-64 genome-wide lentiviral human libraries Table 5. The human ORFeome Collaboration entry clone cDNA plasmid 67 information Table 6. Lentiviral cDNA expression plasmids 68 Table 7. Recruiting clinical trials for FGFR inhibition in breast cancer 165 Table 8. Available lentiviral cDNA expression plasmids 184 viii LIST OF FIGURES Figure 1. The incidence of clinical breast cancer subtypes in the United States 4 of America Figure 2. PAM50 intrinsic breast cancer molecular subtypes 6 Figure 3. Transcript expression of the estrogen receptor (ESR1) in breast 10 tumors based on the patient’s age Figure 4. ESR1 mRNA expression increases with age with no increase in ESR1 11 copy number in breast cancer patients Figure 5. ESR1 gene essentiality across cancer cell lines 12 Figure 6. Candidate oncogenes within the 8p11-12 genomic locus in breast 18-19 cancer Figure 7. Amplification of the 8p11-12 genomic region frequently occurs in 21 cancer Figure 8. The 8p11-12 amplicon genes can predict the survival of breast cancer 22 patients Figure 9. Eukaryotic Initiation Factor 4E-Binding protein (4EBP1) is defined as a 24 translational repressor Figure 10. Important interactions between 4EBP1 and other proteins 27 Figure 11. 4EBP1 acts as a convergence factor for multiple pathways 28 Figure 12. The demonstrated dynamic post-translational modification sites of 30 4EBP1 Figure 13. GeneTree for ENSGT00390000013843 (EIF4EBP1, 4EBP1) 38 Figure 14. 4EBP1 gene expression across 53 normal human tissues 40 Figure 15. TCGA data show many types of cancer overexpress 4EBP1 42 transcripts at high levels Figure 16. Frequency of 4EBP1 mutations in the TCGA cohorts 44 ix Figure 17. Eukaryotic Translation Initiation Factor 4E Binding Protein 49 (EIF4EBP1) transcription factor binding profiles Figure 18. EIF4EBP1 is amplified in human breast cancer 52 Figure 19. cBioPortal TCGA provisional breast cancer data results (2017) 56 showing the top mutational burdens and 4EBP1 alterations in breast cancer Figure 20. Eukaryotic Initiation Factor 4E-Binding Protein 1 (EIF4EBP1) is 57 overexpressed in malignant breast tumors when compared to normal tissue samples in The Cancer Genome Atlas breast cancer cohort Figure 21. EIF4EBP1 is a predicted driver of many cancer types 77 Figure 22. High 4EBP1 expression can predict the prognosis of breast tumor 79 patients Figure 23. 4EBP1 knockdown in normal mammary cells does not inhibit 81 proliferation and levels are comparable to normal primary isolated mammary epithelial cells Figure 24. 4EBP1 is highly expressed and phosphorylated in 8p11-12 breast 84 cancer cells Figure 25. Phosphorylated AKT levels and phosphorylated S6 levels across the 86 models Figure 26. Loss of 4EBP1 does not substantially alter phosphorylated S6 or 88 phosphorylated AKT levels Figure 27. 4EBP1 knockdown inhibits proliferation of ER+ 8p11-12 breast 90 cancer cells and decreases ER levels Figure 28. 4EBP1 knockdown leads to G0/G1 arrest in ER+ 8p11-12 breast 92 cancer cells Figure 29. 4EBP1 knockdown inhibits proliferation of ER- 8p11-12 breast cancer 94 cells Figure 30. 4EBP1 knockdown inhibits proliferation of MCF7 and T47D breast 96 cancer cells Figure 31. 4EBP1 knockdown inhibits proliferation of SUM-229 and SUM-149 97 breast cancer cells Figure 32. Knockdown of 4EBP1 does not drastically alter levels of apoptosis 99 associated proteins x Figure 33. Loss of ER by 4EBP1 knockdown does not alter the levels of NSD3 102 or ASH2L Figure 34. The influence of 4EBP1 on MYC protein levels and varying gene 104 expression levels of MYC family members Figure 35.